Abstract
PURPOSE: Ultrasound-guided fine-needle aspiration biopsy is the gold standard for diagnosing thyroid cancer, but 20% to 35% of nodules remain cytologically indeterminate. This study evaluated the value of molecular testing in diagnosing thyroid cancer and its preoperative risk stratification in the Chinese population. EXPERIMENTAL DESIGN: This multicenter observational study included patients with thyroid nodules admitted to five research centers from January 2021 to June 2023. All samples underwent molecular testing using qPCR or next-generation sequencing (NGS). The study assessed genetic variations in nodules and the diagnostic performance of each test, using stepwise multivariable logistic regression to explore factors affecting lymph node metastases and tumor stage. RESULTS: A total of 1,984 patients with 2,027 thyroid nodules were analyzed. The most common genetic alteration detected was BRAF V600E, followed by TERT promoter and CCDC6-RET fusion. For Bethesda categories II and VI, molecular tests combined with cytology significantly enhanced diagnostic performance, yielding Youden Index values of 0.97 for PCR-8 genes and 0.94 for NGS-28 genes. In cytologically indeterminate nodules, PCR-3 and NGS-8 genes exhibited 85% sensitivity and 100% specificity. Independent risk factors for lymph node metastases included age (OR = 0.97), male sex (OR = 1.45), higher Thyroid Imaging Reporting and Data System grading (OR = 1.50), larger tumor size (OR = 1.13), and multifocal nodules (OR = 1.60). Combined mutations in the 8-gene (OR = 6.43) were significant for the advanced tumor stage. CONCLUSIONS: Molecular testing substantially improves diagnostic accuracy when integrated with cytology, facilitating the diagnosis of cytologically indeterminate nodules and offering prognostic insights for patients with thyroid cancer. See related commentary by Sehgal, p. 4869.